-
EP3650013
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3650013
| EP3650013 - COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.11.2021 Database last updated on 24.07.2024 | |
| Former | Examination is in progress Status updated on 25.03.2021 | ||
| Former | Request for examination was made Status updated on 10.04.2020 | Most recent event Tooltip | 26.11.2021 | Application deemed to be withdrawn | published on 29.12.2021 [2021/52] | Applicant(s) | For all designated states Gilead Pharmasset LLC 333 Lakeside Drive Foster City, CA 94404 / US | [2020/20] | Inventor(s) | 01 /
CHAL, Ben c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA California 94404 / US | 02 /
MOGALIAN, Erik c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA California 94404 / US | 03 /
PAKDAMAN, Rowchanak c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA California 94404 / US | 04 /
OLIYAI, Reza c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA California 94404 / US | 05 /
STEFANIDIS, Dimitrios c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA California 94404 / US | 06 /
ZIA, Vahid c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA California 94404 / US | [2020/20] | Representative(s) | Fairbairn, Angus Chisholm Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [2020/20] | Application number, filing date | 19203320.7 | 30.01.2014 | [2020/20] | Priority number, date | US201361759320P | 31.01.2013 Original published format: US 201361759320 P | US201361772292P | 04.03.2013 Original published format: US 201361772292 P | US201361828899P | 30.05.2013 Original published format: US 201361828899 P | US201361870729P | 27.08.2013 Original published format: US 201361870729 P | US201361897793P | 30.10.2013 Original published format: US 201361897793 P | US201361907332P | 21.11.2013 Original published format: US 201361907332 P | [2020/20] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3650013 | Date: | 13.05.2020 | Language: | EN | [2020/20] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 12.02.2020 | Classification | IPC: | A61K9/16, A61K9/20, A61K31/501, A61K31/513 | [2020/20] | CPC: |
A61K31/7072 (EP,CN,KR,US);
A61K31/4184 (EP,CN,KR,US);
A61K31/381 (EP,KR,US);
A61K31/4025 (EP,KR,US);
A61K31/4178 (US);
A61K31/439 (EP,US);
A61K31/4709 (EP,KR,US);
A61K31/497 (EP,KR,US);
A61K31/4985 (EP,US);
A61K31/5025 (EP,KR,US);
A61K31/513 (EP,KR,US);
A61K31/5377 (EP,US);
A61K31/675 (EP,KR,US);
A61K31/7056 (EP,US);
A61K31/7076 (EP,US);
A61K9/1623 (EP,US);
A61K9/1635 (EP,US);
A61K9/2009 (US);
A61K9/2013 (US);
A61K9/2018 (US);
A61K9/2027 (US);
A61K9/2054 (EP,KR,US);
A61K9/209 (EP,US);
A61K9/28 (US);
A61P1/16 (EP);
A61P31/12 (EP);
A61P31/14 (EP);
A61K2300/00 (KR)
(-)
| C-Set: |
A61K31/381, A61K2300/00 (US,EP);
A61K31/4025, A61K2300/00 (US,EP);
A61K31/4184, A61K2300/00 (US,EP,CN);
A61K31/439, A61K2300/00 (US,EP);
A61K31/4709, A61K2300/00 (US,EP);
A61K31/497, A61K2300/00 (EP,US);
A61K31/4985, A61K2300/00 (EP,US);
A61K31/5025, A61K2300/00 (US,EP);
A61K31/513, A61K2300/00 (US,EP);
A61K31/5377, A61K2300/00 (US,EP);
A61K31/675, A61K2300/00 (EP,US);
A61K31/7056, A61K2300/00 (US,EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/20] | Extension states | BA | 15.10.2019 | ME | 15.10.2019 | Title | German: | KOMBINATIONSFORMULIERUNG ZWEIER ANTIVIRALER VERBINDUNGEN | [2020/20] | English: | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | [2020/20] | French: | FORMULATION DE COMBINAISON DE DEUX COMPOSÉS ANTIVIRAUX | [2020/20] | Examination procedure | 15.10.2019 | Examination requested [2020/20] | 12.11.2020 | Amendment by applicant (claims and/or description) | 24.03.2021 | Despatch of a communication from the examining division (Time limit: M04) | 04.08.2021 | Application deemed to be withdrawn, date of legal effect [2021/52] | 24.08.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/52] | Parent application(s) Tooltip | EP14704502.5 / EP2950786 | Fees paid | Renewal fee | 15.10.2019 | Renewal fee patent year 03 | 15.10.2019 | Renewal fee patent year 04 | 15.10.2019 | Renewal fee patent year 05 | 15.10.2019 | Renewal fee patent year 06 | 27.01.2020 | Renewal fee patent year 07 | 13.01.2021 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [IA]WO2011156757 (GILEAD SCIENCES INC [US], et al) [I] 1-6,8-15 * page 12, line 1 - page 13, line 5 * * example 16 * * page 18, line 17 * [A] 7; | [A] - GERMAN P ET AL, "Lack of clinically significant pharmacokinetic drug-drug interaction between sofosbuvir (GS-7977) and GS-5885 or GS-9669 in healthy volunteers", 63RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES,, (20121101), XP009177074 [A] 1-15 * page 1072A, column r, paragraph l * | [A] - CHIOU D ET AL, "Crystallization of Amorphous Components in Spray-Dried Powders", DRYING TECHNOLOGY, TAYLOR & FRANCIS, PHILADELPHIA, PA, US, (20070101), vol. 25, doi:10.1080/07373930701536718, ISSN 0737-3937, pages 1427 - 1435, XP009108943 [A] 1-15 * abstract * DOI: http://dx.doi.org/10.1080/07373930701536718 | [A] - HILFIKER R ET AL, Relevance of Solid-state Properties for Pharmaceutical products, 20060101, PAGE(S) 1 - 19, (20060101), ISBN 978-3-527-31146-0, XP002525043 [A] 1-15 * the whole document * | [A] - GUILLORY J K ED - BRITTAIN H G, GENERATION OF POLYMORPHS, HYDRATES, SOLVATES, AND AMORPHOUS SOLIDS, POLYMORPHISM IN PHARMACEUTICAL SOLIDS; [DRUGS AND THE PHARMACEUTICAL SCIENCES ; 95], MARCEL DEKKER INC, NEW YORK * BASEL, PAGE(S) I - II,183, (19990101), ISBN 978-0-8247-0237-3, XP002350313 [A] 1-15 * the whole document * * page 213 * | by applicant | US6763607 | US2006189633 | US2010016251 | WO2010132601 | US2010298257 | US7964580 | US2011251152 | US2012107278 | US8178491 | US2013102525 | US2013324740 | US2013324496 | WO2013185093 | US2014017198 | - Modern Pharmaceutics, Marcel Dekker, Inc. |